Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis

被引：0
|
作者：
Soussi, G. [1 ,2 ]
Hercent, A. [3 ]
Gounant, V. [1 ,2 ]
Lupo, A. [4 ]
Cazes, A. [5 ]
Lamoril, J. [3 ]
Guyard, A. [5 ]
Theou-Anton, N. [3 ]
机构：
[1] Univ Paris Cite, Thorac Oncol Dept, Paris, France
[2] Nord Univ Paris Cite, Bichat Claude Bernard Univ Hosp, Canc Inst AP HP, CIC1425 CLIP2 Early Phase Canc Clin Trials Unit, Paris, France
[3] Univ Paris Cite, Canc Inst APHP Nord, Bichat Claude Bernard Univ Hosp, Dept Genet, Paris, France
[4] Univ Paris Cite, Cochin Univ Hosp, Dept Pathol, Paris, France
[5] Nord Univ Paris Cite, Bichat Claude Bernard Univ Hosp, Canc Inst AP HP, Dept Pathol, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; ROS1; fusions; Immunohistochemistry;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP06.03-15
引用
收藏
页码：S489 / S489
页数：1
相关论文
共 50 条
  • [21] Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
    Facchinetti, Francesco
    Rossi, Giulio
    Bria, Emilio
    Soria, Jean-Charles
    Besse, Benjamin
    Minari, Roberta
    Friboulet, Luc
    Tiseo, Marcello
    CANCER TREATMENT REVIEWS, 2017, 55 : 83 - 95
  • [22] Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer
    Zhang, Qing
    Wu, Chunyan
    Ding, Wei
    Zhang, Zhihong
    Qiu, Xueshan
    Mu, Dianbin
    Zhang, Haiqing
    Xi, Yanfeng
    Zhou, Jianhua
    Ma, Liheng
    Fu, Shijun
    Gao, Min
    Wang, Bo
    Deng, Juan
    Lin, Dongmei
    Zhang, Jie
    THORACIC CANCER, 2019, 10 (01) : 47 - 53
  • [23] Non-Small Cell Lung Cancer Targeted Therapy in Case of ROS1 Rearrangement
    Reutova, Elena
    Laktionov, Konstantin
    Ardzinba, Merab
    Meshcheriakova, Nadezhda
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1180 - S1181
  • [24] LORLATINIB ALK/ROS1 inhibitor Treatment of non-small cell lung cancer
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (12) : 715 - 723
  • [25] The routine detection of ROS1 fusion rearrangement in non-small cell lung cancer
    Wu, J.
    Lin, Y.
    He, X.
    He, P.
    Fu, X.
    Gu, X.
    ANNALS OF ONCOLOGY, 2015, 26 : 9 - 9
  • [26] ROS1 immunocytochemistry on cytological specimens in patients with non-small cell lung cancer
    Vlajnic, T.
    Savic, S.
    Bubendorf, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Clinical significance of ROS1 5′ deletions in non-small cell lung cancer
    Capizzi, Elisa
    Dall'Olio, Filippo Gustavo
    Gruppioni, Elisa
    Sperandi, Francesca
    Altimari, Annalisa
    Giunchi, Francesca
    Fiorentino, Michelangelo
    Ardizzoni, Andrea
    LUNG CANCER, 2019, 135 : 88 - 91
  • [28] Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
    Glaser, M.
    Von Levetzow, C.
    Michels, S.
    Nogova, L.
    Katzenmeier, M.
    Wompner, C.
    Schmitz, J.
    Bitter, E.
    Terjung, I.
    Passmann, E.
    Schaufler, D.
    Eisert, A.
    Fischer, R.
    Riedel, R.
    Weber, J. P.
    Hahne, S.
    Merkelbach-Bruse, S.
    Buttner, R.
    Wolf, J.
    Scheffler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S456 - S456
  • [29] Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
    Wang, W-X.
    Xu, C.
    Zhuang, W.
    Tian, Y.
    Xu, J.
    Fang, M.
    Chen, Y.
    Chen, G.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S17 - S17
  • [30] Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
    Liu, Qinghua
    Huang, Qingyan
    Yu, Zhikang
    Wu, Heming
    CLINICAL RESPIRATORY JOURNAL, 2022, 16 (03): : 216 - 225
12345